MarketCap
Facebook
X
Telegram
Edwards Lifesciences Corporation Balance Sheet 2025-2007 | EW
Brief overview of Edwards Lifesciences Corporation's balance sheet structure
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Assets advanced +61.1% to $13.7 billion from $8.5 billion; annual growth near 12.7% reflects a fast increase in scale.
Growth in the asset base was not matched by liabilities: +61.1% versus +26%. The balance sheet moved in a more conservative direction.
Internal capital represents 75.5% of the balance sheet, previously 68.6%. This is a strong capital position.
Cash exceeds interest-bearing debt, producing net debt of -$2.3 billion. The balance sheet therefore carries a net cash position.
Cash accounts for 21.4% of assets versus 10.1% initially. The change indicates the degree of financial flexibility.
By the end of the period, accumulated earnings were $14.2 billion; the change from the start was +134.7%.
Overall assessment
Edwards Lifesciences Corporation has a solid balance sheet cushion. Capital and liquidity support development without excessive reliance on debt.
Annual Balance Sheet Edwards Lifesciences Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-2.32 B | -2.42 B | -512 M | -147 M | -242 M | -561 M | -247 M | 122 M | 218 M | 233 M | 388 M | 729 M | 689 M | 88.9 M | 258 M | - | - | - | - |
Long Term Debt |
598 M | 598 M | 597 M | 596 M | 596 M | 595 M | 594 M | 594 M | 438 M | 822 M | 600 M | 598 M | 593 M | 189 M | 150 M | - | - | - | - |
Long Term Debt Current |
24.5 M | 23.4 M | 22.9 M | 25.5 M | 25.5 M | 27.2 M | 25.5 M | - | 598 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 1.44 B | 1.31 B | 1.34 B | 1.36 B | 1.08 B | 898 M | 820 M | 395 M | 307 M | - | - | - | - |
Total Current Liabilities |
1.81 B | 1.51 B | 1.2 B | 1.02 B | 1.03 B | 894 M | 902 M | 877 M | 1.4 B | 532 M | 476 M | 434 M | 346 M | 347 M | 335 M | 338 M | 290 M | - | - |
Total Liabilities |
3.36 B | 2.99 B | 2.64 B | 2.49 B | 2.67 B | 2.66 B | 2.34 B | 2.18 B | 2.74 B | 1.89 B | 1.56 B | 1.33 B | 1.17 B | 742 M | 643 M | - | - | - | - |
Retained Earnings |
14.2 B | 13.2 B | 8.99 B | 7.59 B | 6.07 B | 4.56 B | 3.74 B | 2.69 B | 1.96 B | 3.91 B | 3.34 B | 2.84 B | 2.05 B | 1.65 B | 1.36 B | 1.12 B | 906 M | - | - |
Total Assets |
13.7 B | 13.1 B | 9.36 B | 8.29 B | 8.5 B | 7.24 B | 6.49 B | 5.32 B | 5.7 B | 4.51 B | 4.06 B | 3.52 B | 2.72 B | 2.22 B | 1.98 B | 1.77 B | 1.62 B | - | - |
Cash and Cash Equivalents |
2.94 B | 3.05 B | 1.13 B | 769 M | 863 M | 1.18 B | 1.18 B | 714 M | 818 M | 930 M | 718 M | 654 M | 420 M | 311 M | 171 M | 396 M | 334 M | 219 M | 142 M |
Book Value |
10.3 B | 10.1 B | 6.72 B | 5.81 B | 5.84 B | 4.57 B | 4.15 B | 3.14 B | 2.96 B | 2.62 B | 2.5 B | 2.19 B | 1.56 B | 1.48 B | 1.34 B | 1.77 B | 1.62 B | - | - |
Total Shareholders Equity |
10.3 B | 10 B | 6.65 B | 5.81 B | 5.84 B | 4.57 B | 4.15 B | 3.14 B | 2.96 B | 2.62 B | 2.5 B | 2.19 B | 1.54 B | 1.47 B | 1.34 B | 1.31 B | 1.16 B | 879 M | 835 M |
All numbers in USD currency
Quarterly Balance Sheet Edwards Lifesciences Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
599 M | 598 M | 598 M | 598 M | 598 M | 598 M | 598 M | 597 M | 597 M | 597 M | 597 M | 597 M | 596 M | 596 M | 596 M | - | 596 M | 596 M | 596 M | 595 M | 595 M | 595 M | 595 M | 595 M | 595 M | 594 M | 594 M | 594 M | 594 M | 594 M | 594 M | 594 M | 594 M | 438 M | 438 M | 438 M | 438 M | 822 M | 822 M | 822 M | 822 M | 597 M | 600 M | 600 M | 600 M | 598 M | 598 M | 598 M | 598 M | 593 M | 593 M | 593 M | 593 M | 189 M | - | - | - | - | - | - | - | - | 178 M |
Total Liabilities |
3.14 B | 2.99 B | 3.07 B | 2.88 B | 2.83 B | 2.99 B | 3.36 B | 2.59 B | 2.55 B | 2.64 B | 2.64 B | 2.56 B | 2.59 B | 2.49 B | 2.42 B | - | 2.58 B | 2.67 B | 2.62 B | - | - | 2.66 B | 2.66 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
14.9 B | 14.6 B | 14.1 B | 13.9 B | 13.5 B | 13.2 B | 12.8 B | 9.71 B | 9.34 B | 8.99 B | 8.62 B | 8.24 B | 7.93 B | 7.59 B | 7.19 B | - | 6.44 B | 6.07 B | 5.73 B | 5.39 B | 4.9 B | 4.56 B | 4.56 B | 4.56 B | 4.56 B | 3.74 B | 3.74 B | 3.74 B | 3.74 B | 2.69 B | 2.69 B | 2.69 B | 2.69 B | 1.96 B | 1.96 B | 1.96 B | 1.96 B | 3.91 B | 3.91 B | 3.91 B | 3.91 B | 3.34 B | 3.34 B | 3.34 B | 3.34 B | 2.84 B | 2.84 B | 2.84 B | 2.84 B | 2.03 B | 2.03 B | 2.03 B | 2.03 B | 1.65 B | 1.65 B | 1.65 B | 1.65 B | 1.36 B | 1.36 B | 1.36 B | 1.36 B | 1.06 B | 1.01 B |
Total Assets |
13.9 B | 13.3 B | 13.3 B | 13.5 B | 13 B | 13.1 B | 13 B | 10.1 B | 9.74 B | 9.36 B | 9.37 B | 9 B | 8.65 B | 8.29 B | 8.64 B | - | 8.42 B | 8.5 B | 8.16 B | 7.66 B | 7.21 B | 7.24 B | 7.24 B | 7.24 B | 7.24 B | 6.49 B | 6.49 B | 6.49 B | 6.49 B | 5.32 B | 5.32 B | 5.32 B | 5.32 B | 5.67 B | 5.67 B | 5.67 B | 5.65 B | 4.51 B | 4.51 B | 4.51 B | 4.51 B | 4.06 B | 4.06 B | 4.06 B | 4.06 B | 3.52 B | 3.52 B | 3.52 B | 3.52 B | 2.71 B | 2.71 B | 2.71 B | 2.71 B | 2.22 B | 2.22 B | 2.22 B | 2.22 B | 1.98 B | 1.98 B | 1.98 B | 1.98 B | 1.73 B | 1.64 B |
Cash and Cash Equivalents |
2.91 B | 2.45 B | 2.69 B | 3.27 B | 3.14 B | 3.05 B | 3.68 B | 1.66 B | 1.23 B | 1.13 B | 1.41 B | 1.05 B | 876 M | 769 M | 1.25 B | 1.2 B | 1.04 B | 863 M | 1.52 B | 1.31 B | 1.17 B | 1.18 B | 1.18 B | 1.18 B | 1.18 B | 1.18 B | 1.18 B | 1.18 B | 1.18 B | 714 M | 714 M | 714 M | 714 M | 818 M | 818 M | 818 M | 818 M | 930 M | 930 M | 930 M | 930 M | 718 M | 718 M | 718 M | 718 M | 654 M | 654 M | 654 M | 654 M | 420 M | 420 M | 420 M | 420 M | 311 M | 311 M | 311 M | 311 M | 171 M | 171 M | 171 M | 171 M | 361 M | 320 M |
Book Value |
10.7 B | 10.3 B | 10.2 B | 10.6 B | 10.2 B | 10.1 B | 9.61 B | 7.5 B | 7.19 B | 6.72 B | 6.73 B | 6.45 B | 6.06 B | 5.81 B | 6.22 B | - | 5.84 B | 5.84 B | 5.54 B | 7.66 B | 7.21 B | 4.57 B | 4.57 B | 7.24 B | 7.24 B | 6.49 B | 6.49 B | 6.49 B | 6.49 B | 5.32 B | 5.32 B | 5.32 B | 5.32 B | 5.67 B | 5.67 B | 5.67 B | 5.65 B | 4.51 B | 4.51 B | 4.51 B | 4.51 B | 4.06 B | 4.06 B | 4.06 B | 4.06 B | 3.52 B | 3.52 B | 3.52 B | 3.52 B | 2.71 B | 2.71 B | 2.71 B | 2.71 B | 2.22 B | 2.22 B | 2.22 B | 2.22 B | 1.98 B | 1.98 B | 1.98 B | 1.98 B | 1.73 B | 1.64 B |
Total Shareholders Equity |
10.6 B | 10.3 B | 10.2 B | 10.5 B | 10.1 B | 10 B | 9.61 B | 7.5 B | 7.19 B | 6.65 B | 6.73 B | 6.45 B | 6.06 B | 5.81 B | 6.22 B | 5.94 B | 5.84 B | 5.84 B | 5.54 B | 5.13 B | 4.66 B | 4.57 B | 4.57 B | 4.57 B | 4.57 B | 4.15 B | 4.15 B | 4.15 B | 4.15 B | 3.14 B | 3.14 B | 3.14 B | 3.14 B | 2.96 B | 2.96 B | 2.96 B | 2.96 B | 2.62 B | 2.62 B | 2.62 B | 2.62 B | 2.5 B | 2.5 B | 2.5 B | 2.5 B | 2.19 B | 2.19 B | 2.19 B | 2.19 B | 1.54 B | 1.54 B | 1.54 B | 1.54 B | 1.47 B | 1.48 B | 1.48 B | 1.48 B | 1.33 B | 1.34 B | 1.34 B | 1.34 B | 1.23 B | 1.12 B |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Edwards Lifesciences Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Britain
Israel
Canada
China
